Circulating tumor tissue modified viral human papillomavirus DNA (TTMV-HPV DNA) (TTMV-HPV DNA)

Circulating tumor tissue modified viral human papillomavirus DNA (TTMV-HPV DNA) is a specialized liquid biopsy biomarker used to detect and monitor human papillomavirus (HPV)-associated malignancies, particularly oropharyngeal squamous cell carcinoma [1][2]. Unlike standard viral DNA, TTMV-HPV DNA consists of viral genomic fragments that have been integrated into the host genome or otherwise modified by the tumor's cellular machinery before being shed into the bloodstream [2][3]. This biomarker is highly specific to the tumor tissue, allowing for the non-invasive quantification of tumor burden and the detection of minimal residual disease following treatment [3][4]. While TTMV-HPV DNA is not a therapeutic target for drugs, its presence and concentration guide clinical decision-making for therapies such as radiation, chemotherapy, and immunotherapy [1][5]. It has demonstrated significant clinical utility in identifying cancer recurrence significantly earlier than traditional imaging modalities, thereby facilitating earlier intervention [3]. As a molecular diagnostic tool, it represents a critical advancement in the management of HPV-driven cancers by providing a real-time assessment of treatment response [4][5].

Other names

TTMV-HPV DNAHPV ctDNACirculating tumor HPV DNANavDx

Not applicable (Biomarker)